Conflict of interest Dr Wiegell has received speakers’ honoraria from PhotoCure and travelling grants from Galderma. Dr Wulf has received speakers’ honoraria from and is a consultant for Galderma and PhotoCure. Dr Szeimies received financial support for performing clinical trials, has served as a consultant for, and has received speakers’ honoraria from Galderma. He has received financial support from Biocam GmbH, Energist, Medac, 3M, PhotoCure, Waldmann Medizintechnik and Wavelight AG for performing clinical trials. Dr Basset-Seguin does consultant work for Galderma, 3M, Meda, PhotoCure,Vichy, Roche, Novartis and P Fabre. She has received financial support from Photocure, 3M, Meda and Genentech for performing clinical trials. Dr Bissonnette has received speakers’ honoraria from Galderma and Leo Pharma. He has received financial support from PhotoCure, Graceway, Galderma, Leo Pharma and DUSA Pharmaceuticals for performing clinical trials. Dr Gerritsen has received speakers’ honoraria from Galderma, 3M and Medac and joined Galderma advisory board. She has received financial support from PhotoCure, Galderma, 3M, and Medac for performing clinical trials. Dr Gilaberte has received speakers’ honoraria from Galderma. Dr Calzavara-Pinton has received speakers’ honoraria from Galderma, Pfizer, Schering-Plough, La Roche Posay, Pierre Fabre, Leo and Difa-Cooper. He has received financial support from PhotoCure ASA, Pfizer, Difa-Cooper, Serono and Schering-Plough for performing clinical trials. Dr Morton has received financial speakers’ honoraria from Galderma and is a member of Leo Pharma and Basilea advisory boards. He has received travel scholarships from 3M, PhotoCure, and Phototherapeutics Ltd. Dr Sidoroff has no conflict of interest. Dr Braathen has received speakers’ honoraria from Galderma and received financial support from Galderma and PhotoCure for performing clinical trials. He is a consultant for PhotoCure.
Daylight photodynamic therapy for actinic keratosis: an international consensus
International Society for Photodynamic Therapy in Dermatology
Article first published online: 23 DEC 2011
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 26, Issue 6, pages 673–679, June 2012
How to Cite
Wiegell, S.R., Wulf, H.C., Szeimies, R.-M., Basset-Seguin, N., Bissonnette, R., Gerritsen, M.-J.P., Gilaberte, Y., Calzavara-Pinton, P., Morton, C.A., Sidoroff, A. and Braathen, L.R. (2012), Daylight photodynamic therapy for actinic keratosis: an international consensus. Journal of the European Academy of Dermatology and Venereology, 26: 673–679. doi: 10.1111/j.1468-3083.2011.04386.x
The recommendations set forth in this article have been prepared for dermatologists on behalf of the International Society for Photodynamic Therapy in Dermatology and reflect the best data available at the time this report was prepared. Caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations of this report. It may be necessary or even desirable to depart from the recommendations in the interests of specific patients or special circumstances. Just as adherence to these recommendations may not constitute a defense against a claim of negligence, so deviation from them should not necessarily be deemed negligent.
Funding sources The work of the IPDT was supported by an educational grant from Galderma International, Paris, France.
- Issue published online: 23 MAY 2012
- Article first published online: 23 DEC 2011
- Received: 14 July 2011; Accepted: 14 November 2011
Photodynamic therapy (PDT) is an attractive therapy for non-melanoma skin cancers including actinic keratoses (AKs) because it allows treatment of large areas; it has a high response rate and results in an excellent cosmesis. However, conventional PDT for AKs is associated with inconveniently long clinic visits and discomfort during therapy. In this article, we critically review daylight-mediated PDT, which is a simpler and more tolerable treatment procedure for PDT. We review the effective light dose, efficacy and safety, the need for prior application of sunscreen, and potential clinical scope of daylight-PDT. Three randomized controlled studies have shown that daylight-mediated PDT is an effective treatment of thin AKs. Daylight-mediated PDT is nearly pain-free and more convenient for both the clinics and patients. Daylight-mediated PDT is especially suited for patients with large field-cancerized areas, which can easily be exposed to daylight. Further investigations are necessary to determine at which time of the year and in which weather conditions daylight-mediated PDT will be possible in different geographical locations.